Skip to main content

Spyre Therapeutics, Inc. (SYRE) Stock Analysis

SellModerate Confidence

Healthcare · Biotechnology

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $74.00: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Below-average business quality.

Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies targeting IBD and rheumatic diseases, with programs in SPY001/α4β7, SPY002/TL1A, and SPY003/IL-23 as monotherapies and combinations. No revenue; funded by ~$756.5M cash/equivalents as of Dec 31,... Read more

$74.00+9.6% A.UpsideScore 4.7/10#113 of 158 Biotechnology
Stop $68.82Target $81.12(analyst − 10%)A.R:R 0.6:1
Analyst target$90.13+21.8%15 analysts
$81.12our TP
$74.00price
$90.13mean
$64
$115

Sell if holding. Engine safety override at $74.00: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.

Passes 5/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: aggressive.

Val6.0Qual1.4Grw5.0Mom5.1Sent7.4Ins3.9Peer5.2Tech4.2Risk2.34.7OVERALL

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: SPY001, SPY002, SPY072 and SPY003 programs
Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-23.8
Mkt Cap$6.2B
EV/EBITDA—
Profit Mgn0.0%
ROE-25.2%
Rev Growth—
Beta2.94
DividendNone
Rating analysts21

Quality Signals

Piotroski F2/9

Options Flow

P/C0.24bullish
IV81%elevated
Max Pain$23-69.6% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductSPY001, SPY002, SPY072 and SPY003 programs
    10-K Item 1A: 'We are substantially dependent on the success of the SPY001, SPY002, SPY072 and SPY003 programs, alone or in combination'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
2.2
Current Ratio
5.0
Moat
5.0
Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Volatile — 7.9% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Implied Vol
0.0
Beta
0.2
Days To Cover
0.7
Short Interest
1.9
Max Pain Risk
3.0
Put Call
10.0
High short interest justified: 16%High IV: 81%Above max pain $22Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
GatesA.R:R 0.6 < 1.5@spotEARNINGS PROXIMITY 5d<=7dMomentum 5.1<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.1>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive
RSI
78 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $46.27Resistance $75.00

Price Targets

$69
$81
A.Upside+9.6%
A.R:R0.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)
! Reward/Risk 0.6:1 at current price — below 1.5:1 minimum
! EARNINGS_PROXIMITY:5d<=7d

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SYRE stock a buy right now?

Sell if holding. Engine safety override at $74.00: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $68.82. Score 4.7/10, moderate confidence.

What is the SYRE stock price target?

Take-profit target: $81.12 (+9.6% upside). Prior stop was $68.82. Stop-loss: $68.82.

What are the risks of investing in SYRE?

Concentration risk — Product: SPY001, SPY002, SPY072 and SPY003 programs; Quality below floor (1.4 < 4.0).

Is SYRE overvalued or undervalued?

Spyre Therapeutics, Inc. trades at a P/E of N/A (forward -23.8). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about SYRE?

21 analysts cover SYRE with a consensus score of 4.5/5. Average price target: $90.

What does Spyre Therapeutics, Inc. do?Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies targeting IBD and rheumatic diseases,...

Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies targeting IBD and rheumatic diseases, with programs in SPY001/α4β7, SPY002/TL1A, and SPY003/IL-23 as monotherapies and combinations. No revenue; funded by ~$756.5M cash/equivalents as of Dec 31, 2025 with net losses of $155.2M in 2025.

Related stocks: NVAX (Novavax, Inc.) · AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · HRMY (Harmony Biosciences Holdings, I) · INVA (Innoviva, Inc.)